Using the Xerna TME Panel, researchers analyzed pre-treatment tumor biopsies to classify patients who went on to receive durvalumab maintenance therapy or active surveillance only as immune score ...

WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”) is a precision medicine company using an innovative RNA-expression based biomarker platform to predict ...

BOSTON--(BUSINESS WIRE)--Genialis, a leader in applied data science for the development of precision medicines, today announced it will leverage its proprietary ResponderID AI platform technology to ...

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s ...

Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis ...

With a new partnership with India-based 4baseCare, Genialis addresses the gap in data representation to ensure its AI/ML models work in more diverse populations Over 15,000 patient samples from a ...

Genialis has created ResponderID, a machine-learning platform that unravels complex biological signatures from patient data to deliver next-generation biomarkers for diagnostic and drug development.

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s ...

Better 24-month survival was achieved when durvalumab was used for maintenance compared to surveillance in esophagogastric adenocarcinoma patients with“high” Xerna TME Panel immune scores, despite ...

Xerna TME Panel has potential to predict patient responses to angiogenic- and immune-targeted therapies WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”) is a ...